FDA backs Vytorin For Kidney Disease Patients

Posted Monday, October 31, 2011 --- Noon

WASHINGTON (AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.

The agency's review also found no new safety concerns with Vytorin, which came under scrutiny for potential cancer risks in 2008.

Merck & Co. has asked the FDA to approve the drug for a new use in reducing heart-related problems chronic kidney disease patients. The combination pill is already cleared to reduce bad cholesterol.

FDA says that Vytorin lowered kidney disease patients' heart-related problems by 16 percent compared with placebo.

On Wednesday, a panel of non-government FDA advisers will vote on the new use.

Vytorin, a multibillion-dollar drug for Merck, combines two brand-name cholesterol pills Zocor and Zetia.

Copyright 2011. The Associated Press.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
NBC15 615 Forward Drive Madison, Wisconsin 53711 Business: 608-274-1515 Newsroom: 608-274-1500
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 132930053 - nbc15.com/a?a=132930053